VIVITRA - 150MG Applepharmaceutical

DESCRIPTION :

vivitra 150 mg is a group of medicines which belongs to antineoplastic medication. vivitra 150 mg injection is a chemotherapy drug. It is recommended that Vivitra 150mg be administered under the guidance of a qualified physician experienced in the use of cancer chemotherapeutic agents.



USES :

The injection vivitra 150 mg is used alone or combined with other medicine for the treatment in patients who suffer . vivitra 150 mg injection from metastatic breast cancer.

The drug also indicated with a combination of other medicine for the treatment of certain types of stomach or esophagus cancer in some persons.



WORK AS

vivitra 150 mg Different type of breast cancer cells has a higher than normal level of a protein called HER2 (human epidermal growth factor receptor 2) on their surface. These HER2 receptors get signals which stimulate the tumor cells to develop and reproduce. But breast cancer cells with too many HER2 receptors can Choice too many growth signals and so start developing and proliferating too much and too fast.

Vivitra acts by adhering itself to the HER2 receptors on the surface of breast cancer cells and stopping them from collecting growth signals. By stopping the signals, Vivitra can slow or inhibit the growth of breast cancer and the drug is an immune targeted therapy. In addition to inhibiting HER2 receptors, Trastuzumab can also help to fight against breast cancer by attentive the immune system to damage the cancer cells onto which it is attached.



DOSAGE :

The injection vivitra 150 mg should not mix with other drugs and do not administer as an intravenous push or bolus.

Trastuzumab should not be substitute for or with ado-Trastuzumab emtansine

Adjuvant treatment, breast cancer:

The drug given according to one of the following doses and schedules for a 52 weeks total of trastuzumab treatment:

During combination with paclitaxel, docetaxel, or docetaxel /Carboplatin:

Starting dose of 4 mg/kg as an IV (intravenous infusion) over 90 minutes followed at 2 mg/kg as an IV (intravenous infusion) over 30 minutes weekly during treatment of chemotherapy given with paclitaxel or docetaxel for first 12 weeks or 18 weeks (docetaxel/carboplatin) The Vivitra dose for One week following the last weekly administers Trastuzumab at 6 mg/kg as an IV (intravenous infusion) over 30 to 90 minutes every three weeks.

The injection given as a single agent within three weeks following completion of multi-modality, anthracycline-based chemotherapy regimens: For an intravenous infusion over 90 minutes: Initial dose at 8 mg/kg

Successive doses at 6 mg/kg over 30 to 90 minutes every three weeks as an intravenous infusion.

Adjuvant treatment stretching beyond one year is not recommended.

Metastatic Treatment, Breast Cancer:

Vivitra administrated alone or in combination with paclitaxel, at a starting dose of 4 mg/kg as a 90-minute intravenous infusion continued by successive once weekly doses of 2 mg/kg as 30-minute intravenous infusions until disease development.

Metastatic Gastric Cancer:

Vivitra administrated at a starting dose of 8 mg/kg as a 90-minute IV intravenous infusion continued by successive doses of 6 mg/kg as an intravenous infusion over 30 to 90 minutes every three weeks until disease development.



PRECAUTION :

Embryo fetal damage

Vivitra 150mg is contraindicated to pregnancy period. Avoid becoming pregnancy during this therapy. Use efficient contraceptives during treatment




Cardiomyopathy

Patient getting Vivitra 150mg injection have increased risk of exposing to cardiac disorders. Provide alternative therapy management In serious condition, treatment should be discontinuing.

vivitra 150 mg injection

Pulmonary toxicity

Some serious fatal cases of pulmonary toxicity occur during Vivitra 150mg treatment.




Infusion reactions

During Vivitra 150mg treatment some life-threatening infusion reactions are produced.

In serious infusion reactions, Stop the Vivitra 150mg treatment permanently.

Patient should be treated with premedication before starting the infusion to overcome the such problem, During Vivitra 150mg treatment. Use with Caution.




Therapy induced neutropenia

Higher incidence of neutropenia occurs during Vivitra 150mg treatment.




DRUG SUMMARY
Probably no contraindicated occurs.
The patients are contraindicated to the component present in the Vivitra 150mg, Hence Hypersensitivity reactions are occurring.


STORAGE
Store the drug at 2℃ to 8℃ (refrigerator temperature) Protected the vial away from heat & light Stored at 2℃ to 8℃ for 28 days after reconstitution Stored Vivitra 150mg diluted bag at 2℃ to 8℃ for 24 hours.


MISSED DOSE
The drug Missing vivitra 150 mg injection doses can decrease their usefulness and raises the probability of developing drug resistance, that makes this drug lose their potency. For best results, it is important to accept each scheduled dose of Trastuzumab medication as instructed. If you miss a dose, leave the missed dose and continue with your regular dosing schedule. Do not have two doses to make up for a missed one. If you are not sure about what to do after missing a dose, the take advice with doctor or pharmacist.


SIDE EFFECTS :
Common side effects:
Redness at injection site (IV)
Muscle/joint/back pain
Insomnia
Tiredness
Mild skin rash
Stuffy nose
Sinus pain


Serious side effects:
Increased coughing
Sudden unexplained weight gain
Unusual tiredness
Easy bruising or bleeding
Fast or pounding heartbeat
Increased coughing

Contact Details :

    Phone : +91-9987711567 

    Email : applepharmaceutical@gmail.com

    Email : info@myapplepharma.com

    0091-9987711567

    applepharmaceuticals